Drugs / [177Lu]Lu-RTX-2358
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07689643 | Apr 2026 → Sep 2027 expected | non-small cell lung carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-RTX-2358 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07689643 ↗ |
| Modality | Other / unclassified | “is a lutetium-177-labeled fibroblast activation protein (FAP)-targeted radioligand” NCT07689643 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07689643 ↗ |
| Target | FAP | “fibroblast activation protein (FAP)-targeted” NCT07689643 ↗ |